We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
126
Eli Lilly
LLY
$1.07T
$390K 0.06%
500
-100
-17% -$77.7K
TARA icon
127
Protara Therapeutics
TARA
$227M
$372K 0.06%
122,690
– –
FULC icon
128
Fulcrum Therapeutics
FULC
$286M
$367K 0.06%
53,349
-437,183
-89% -$2.34M
PYPD icon
129
PolyPid
PYPD
$87.8M
$367K 0.06%
103,950
+23,870
+30% +$69.9K
VTYX
130
DELISTED
Ventyx Biosciences
VTYX
$361K 0.06%
168,600
-113,000
-40% -$183K
NRIX icon
131
Nurix Therapeutics
NRIX
$2.62B
$355K 0.05%
31,200
+10,000
+47% +$108K
BHVN icon
132
CALL
Biohaven
BHVN
$2.1B
$353K 0.05%
+25,000
New +$446K
MDGL icon
133
Madrigal Pharmaceuticals
MDGL
$12.1B
$319K 0.05%
1,054
-436
-29% -$130K
GPCR icon
134
Structure Therapeutics
GPCR
$3.61B
$311K 0.05%
15,000
-20,619
-58% -$453K
STOK icon
135
Stoke Therapeutics
STOK
$2.12B
$310K 0.05%
27,285
-2,800
-9% -$26.6K
INMB icon
136
PUT
INmune Bio
INMB
$49.4M
$301K 0.05%
+130,200
New +$955K
APLS
137
DELISTED
Apellis Pharmaceuticals
APLS
$294K 0.05%
17,000
– –
ANSC
138
Agriculture & Natural Solutions Acquisition Corp
ANSC
$294K 0.05%
27,062
-20,000
-42% -$215K
JAZZ icon
139
Jazz Pharmaceuticals
JAZZ
$17B
$292K 0.04%
+2,750
New +$299K
GOSS icon
140
Gossamer Bio
GOSS
$86.3M
$279K 0.04%
227,228
– –
BMRN icon
141
BioMarin Pharmaceuticals
BMRN
$11.6B
$269K 0.04%
4,900
– –
ITOS
142
DELISTED
iTeos Therapeutics
ITOS
$269K 0.04%
26,937
-74,159
-73% -$597K
UCFI
143
CN Healthy Food Tech Group
UCFI
$258K 0.04%
25,000
– –
SMMT icon
144
Summit Therapeutics
SMMT
$11B
$255K 0.04%
+12,000
New +$274K
ATYR
145
PUT
aTyr Pharma
ATYR
$51M
$254K 0.04%
+50,000
New +$197K
VYGR icon
146
Voyager Therapeutics
VYGR
$191M
$249K 0.04%
79,945
+4,400
+6% +$14.2K
TXMD icon
147
TherapeuticsMD
TXMD
$23.5M
$243K 0.04%
209,210
-60,950
-23% -$73.9K
ASND icon
148
Ascendis Pharma A/S
ASND
$16.7B
$242K 0.04%
1,402
– –
QNCX icon
149
Quince Therapeutics
QNCX
$28.5M
$236K 0.04%
715
– –
CNTX icon
150
Context Therapeutics
CNTX
$47.3M
$230K 0.04%
351,094
– –
4 5
6
7 8

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.